Recent advances on innovative bioactive glass-hydroxyapatite composites for bone tissue applications: Processing, mechanical properties, and biological performance

New Hydroxyapatite-Bioactive Glass composites, xHA-(1-x)BG (x = 25, 50, and 75 wt %), are developed using HA and BGMS10 glass powders co-milled up to 2 h prior to Spark Plasma Sintering (SPS). Ball milling (BM) promoted the consolidation of HA-rich powders, whereas hindered the densification of 25HA-75BG samples. HA crystallite size is reduced from > 200 nm (unmilled) to 60 (x = 25 %) or 88 nm (x = 75 %) when using 2 h milled mixtures. Glass crystallization occurred in 75HA-25BG samples processed by SPS at 950 C: a negligeable effect in the amount of the residual amorphous phase (12.3-13.3 wt %) is produced by BM, while changes are observed in the relative content of crystalline phases, with SiO2 increases from 8.5 to 13.1 wt %, whereas alpha-and beta-CaSiO3 correspondingly decrease. Superior Young's modulus and Vickers hardness (130 GPa and 726, respectively) are obtained in HA rich products. Biological tests evidenced that the milling treatment does not determine negative consequences on cells viability.

Automated summary

New Hydroxyapatite-Bioactive Glass composites were successfully developed in this study using different milling times to modify the properties and crystal structure of the materials. Ball milling promoted the consolidation of HA powders and reduced the crystallite size. Spark Plasma Sintering process changed the crystal structure and composition of the composites, affecting the mechanical properties. Moreover, the milling treatment showed no negative effects on cell viability.